# Study of Efficacy and Safety of Canakinumab in Pediatric Patients With Kawasaki Disease

> **NCT02980263** · PHASE2 · WITHDRAWN · sponsor: **Novartis Pharmaceuticals**

## Conditions studied

- Kawasaki Disease

## Interventions

- **DRUG:** Canakinumab

## Key facts

- **NCT ID:** NCT02980263
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2016-11-15
- **Primary completion:** 2017-11-30
- **Final completion:** 2017-11-30
- **Target enrollment:** 0 (ACTUAL)
- **Last updated:** 2017-02-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02980263

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02980263, "Study of Efficacy and Safety of Canakinumab in Pediatric Patients With Kawasaki Disease". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02980263. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*